What is KTTA stock price today?

KTTA (Pasithea Therapeutics Corp) stock is trading at $0.75 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is KTTA stock going up or down today?

KTTA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy KTTA stock now?

The decision to buy KTTA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is KTTA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for KTTA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is KTTA stock overvalued or undervalued?

Use our DCF valuation calculator to determine if KTTA is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is KTTA's P/E ratio?

P/E ratio data for KTTA will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is KTTA's market cap?

KTTA (Pasithea Therapeutics Corp) has a market capitalization of $0.02 billion, making it a small-cap stock.

What is KTTA's price to book ratio?

KTTA trades at a price-to-book (P/B) ratio of 0.36, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does KTTA pay dividends?

KTTA does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is KTTA's dividend yield?

KTTA does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is KTTA stock a good long-term investment?

KTTA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is KTTA's revenue growth rate?

KTTA has shown revenue growth of 15.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for KTTA are available on our dashboard with complete income statement analysis.

What are the risks of investing in KTTA?

Key risks for KTTA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does KTTA compare to its competitors?

Compare KTTA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize KTTA's performance and positioning.

What is KTTA's stock price target for 2026?

Our AI model provides price targets for KTTA based on fundamental analysis: Bull case $0.97 (+30%), Base case $0.86 (+15%), Bear case $0.67 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about KTTA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for KTTA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is KTTA's next earnings report?

KTTA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

KTTA - Pasithea Therapeutics Corp

NYSE * Health Care * Biotechnology

$0.75

$-0.04 (-5.58%)

About Pasithea Therapeutics Corp

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

KTTA Key Statistics

Market Cap

$19.70M

P/B Ratio

0.36

EPS

$-2.91

Revenue Growth

+15.0%

Employees

How KTTA Compares to Peers

KTTA has the fastest revenue growth among competitors

KTTA is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
KTTA(This stock)	$19.70M	N/A	15%	0.0%	-
AMGNAmgen Inc	$188.34B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$171.97B	20.4	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.81B	28.4	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$78.87B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Pasithea Therapeutics Corp Company Information

Headquarters: California; U.S.A
Website: www.pasithea.com
Sector: Health Care
Industry: Biotechnology

About Pasithea Therapeutics Corp

KTTA Key Statistics

How KTTA Compares to Peers

Pasithea Therapeutics Corp Company Information

Upcoming Events for KTTA